News

The CMTA is a global leader in the acceleration of CMT research and pre-clinical testing. The CMTA will be attending the BIO annual meeting in Boston and have availability for partner meetings from Monday June 5 through Wednesday June 7. ...

GLENOLDEN, PA, USA, May 10, 2023, EINPresswire.com — Tech entrepreneur David Apple joined the CMTA Board of Directors on April 25, saying he is thrilled to become part of the generation that will find treatments and cures for CMT. CMT is ...

CMT2E is caused by dominant or recessive mutations in the Nefl gene which codes for the neurofilament protein L protein (NFL). This proposal takes advantage of mouse models of dominant and recessive CMT2E, one a heterozygous “knockin” of the N98S ...

In people with CMT1X cell-to-cell communication within the peripheral nervous system is affected, leading to a breakdown in nerve signals resulting in a progressive muscular atrophy (wasting or loss of muscle tissue), weakness, and loss of sensation in the limbs. ...

CMT is a genetic disease caused by distinct changes in the DNA of a patient and these are typically transmitted in families. Although over 100 different genes, each causing a CMT subtype, have already been identified, more than 50% of ...